To identify key molecules involved in ferroptosis resistance in cancer, we leveraged genomic or transcriptomic data of a thousand human cancer cell lines and their pharmacological responses against FINs, including RSL3, ML210, and ML162, which targeting GPX4, and erastin, which is a system xc- inhibitor, obtained from the DepMap database. This evidence concerns the gene GPX4 and cancer.